Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies

We carried out a multicenter dose-escalation phase I study of oral OPB-51602, a signal transducer and activator of transcription 3 phosphorylation inhibitor, in patients with relapsed or refractory hematological malignancies to evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics, and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Ogura, Michinori, Uchida, Toshiki, Terui, Yasuhito, Hayakawa, Fumihiko, Kobayashi, Yukio, Taniwaki, Masafumi, Takamatsu, Yasushi, Naoe, Tomoki, Tobinai, Kensei, Munakata, Wataru, Yamauchi, Takeshi, Kageyama, Akiko, Yuasa, Miyuki, Motoyama, Masaaki, Tsunoda, Takeshi, Hatake, Kiyohiko
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Ltd 2015
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4520642/
https://ncbi.nlm.nih.gov/pubmed/25912076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12683
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge